文献速递消化系统肿瘤

局部进展期胃癌腹腔镜远端胃切除术的长期结局:KLASS-02-RCT随机临床试验

Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial.
PubMed 文献 · J Clin Oncol · 2020-08-20

KLASS-02-RCT是一项III期开放标签随机对照试验,评估局部进展期胃癌腹腔镜远端胃切除联合D2淋巴结清扫与开腹手术相比的3年无复发生存率非劣效性。共1050例患者随机分组,最终分析腹腔镜组492例、开腹组482例。腹腔镜组早期和晚期并发症均更少。

要点

  • 腹腔镜远端胃切除联合D2清扫的3年无复发生存率非劣效于开腹手术。
  • 腹腔镜组早期并发症15.7% vs 23.4%,晚期并发症4.7% vs 9.5%,均显著更低。
  • 腹腔镜远端胃切除联合D2清扫可作为局部进展期胃癌的潜在标准治疗选择。

核心结论

  • 局部进展期胃癌行腹腔镜远端胃切除联合D2淋巴结清扫,其无复发生存与开腹手术相当,可作为潜在标准治疗选择。

研究设计与样本

  • III期、开放标签、随机对照试验,纳入组织学证实适合远端胃大部切除的局部进展期胃腺癌患者。
  • 2011年11月至2015年4月共随机分配1050例患者至腹腔镜组(n=524)或开腹组(n=526),排除后腹腔镜组492例、开腹组482例纳入分析。
  • 主要终点为3年无复发生存率,非劣效性HR上限设定为1.43。

关键数值与推荐

  • 非劣效性界值:HR上限为1.43。
  • 3年无复发生存率:腹腔镜组80.3%(95%CI 76.0%-85.0%),开腹组81.3%(95%CI 77.0%-85.0%)。

临床怎么用

  • 对于适合远端胃大部切除的局部进展期胃腺癌,腹腔镜远端胃切除联合D2淋巴结清扫可作为开腹手术的替代选择。
  • 腹腔镜手术与更低的早期和晚期并发症发生率相关,尤其是肠梗阻。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: It is unclear whether laparoscopic distal gastrectomy for locally advanced gastric cancer is oncologically equivalent to open distal gastrectomy. The noninferiority of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer compared with open surgery in terms of 3-year relapse-free survival rate was evaluated. PATIENTS AND METHODS: A phase III, open-label, randomized controlled trial was conducted for patients with histologically proven locally advanced gastric adenocarcinoma suitable for distal subtotal gastrectomy. The primary end point was the 3-year relapse-free survival rate; the upper limit of the hazard ratio (HR) for noninferiority was 1.43 between the laparoscopic and open distal gastrectomy groups. RESULTS: From November 2011 to April 2015, 1,050 patients were randomly assigned to laparoscopy (n = 524) or open surgery (n = 526). After exclusions, 492 patients underwent laparoscopic surgery and 482 underwent open surgery and were included in the analysis. The laparoscopy group, compared with the open surgery group, suffered fewer early complications (15.7% v 23.4%, respectively; P = .0027) and late complications (4.7% v 9.5%, respectively; P = .0038), particularly intestinal obstruction (2.0% v 4.4%, respectively; P = .0447). The 3-year relapse-free survival rate was 80.3% (95% CI, 76.0% to 85.0%) for the laparoscopy group and 81.3% (95% CI, 77.0% to 85.0%; log-rank P = .726) for the open group. Cox regression analysis after stratification by the surgeon revealed an HR of 1.035 (95% CI, 0.762 to 1.406; log-rank P = .827; P for noninferiority = .039). When stratified by pathologic stage, the HR was 1.020 (95% CI, 0.751 to 1.385; log-rank P = .900; P for noninferiority = .030). CONCLUSION: Laparoscopic distal gastrectomy with D2 lymphadenectomy was comparable to open surgery in terms of relapse-free survival for patients with locally advanced gastric cancer. Laparoscopic distal gastrectomy with D2 lymphadenectomy could be a potential standard treatment option for locally advanced gastric cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hyung WJ, Yang HK, Park YK, et al. Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial. J Clin Oncol. 2020. PMID: 32816629. doi:10.1200/JCO.20.01210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。